Surprise! Pfizer And Lilly File Tanezumab For Pain With FDA Despite Safety Questions

 
• By Jessica Merrill

The partners have filed the first-in-class NGF inhibitor at the lower 2.5mg dose for the treatment of osteoarthritis pain, despite the drug’s challenging safety profile.

Surprise confetti
The prospects for tanezumab are uncertain • Source: Shutterstock

More from Neurological

More from Therapy Areas